透過您的圖書館登入
IP:44.221.43.88
  • 學位論文

異甘草素對人類子宮內膜癌及卵巢癌細胞生長及移行能力之抑制效果

Inhibitory Effects of Isoliquiritigenin on the Proliferation and Migration of Human Endometrial Cancer and Ovarian Cancer Cells

指導教授 : 夏詩閔
共同指導教授 : 黃翠琴(Tsui-Chin Huang)

摘要


子宮內膜癌 (endometrial cancer)及卵巢癌 (ovarian cancer)好發於停經後的婦女,在歐美國家是常見的癌症,在台灣因女性普遍使用賀爾蒙補充治療,其發生率也攀升至婦科癌症的第一名。近幾年西方國家開始普遍使用中草藥療法,異甘草素 (isoliquiritigenin, ISL)為從甘草植物中萃取出之黃酮類 (flavonoid)活性化合物,先前的研究結果發現,異甘草素具有抗氧化、抗發炎以及抑制腫瘤的效果,而本研究想要探討異甘草素對人類子宮內膜癌及卵巢癌細胞的抗腫瘤效果。分別利用子宮內膜癌細胞株HEC-1A、RL95-2及卵巢癌細胞株OVCAR5和ES-2進行研究,分別介入異甘草素後,觀察其細胞增生、細胞週期、細胞凋亡 (apoptosis)和細胞自噬 (autophagy)相關蛋白之表現量,最後以傷口癒合試驗來觀察異甘草素對癌細胞的抑制效果。實驗結果發現:1. 異甘草素不管在劑量效應還是時間效應上,都能夠顯著抑制癌細胞的生長;2. 異甘草素能夠造成細胞週期停滯於G2/M期;3. 異甘草素會促進細胞凋亡及細胞自噬作用相關蛋白LC3BⅡ的表現量增加;4. 異甘草素會抑制子宮內膜癌細胞的移行能力 (migration)。從本研究結果可以得知,異甘草素對於抑制子宮內膜癌及卵巢癌細胞生長具有多重效果,在治療子宮內膜癌及卵巢癌方面非常具有潛力。

並列摘要


Endometrial cancer and ovarian cancer occurs in women after menopause, is the most common cancer in women in the United States. In Taiwan, due to the widespread use of hormone replacement therapy, the incidence of gynecologic cancer climbed to first name. In recent years, Western countries began the widespread use of herbal therapies, Isoliquiritigenin (ISL), one of the active components in licorice plant flavonoids, in past study, ISL have antioxidantion, anti-inflammatory and tumor suppression effect. In this study, we investigated the antitumor effect of ISL on human endometrial cancer and ovarian cancer cell in vitro. HEC-1A and RL95-2 endometrial cancer cell lines and OVCAR5 and ES-2 ovarian cancer cell lines were used as targets. We examined the effects of ISL on cell proliferation, cell cycle regulation and apoptosis or autophagy related protein expression. Further, we investigated the effects of ISL on migration of cancer cells. ISL significantly inhibited the proliferation of cancer cell lines in a dose-dependent and time-dependent manner. Flow cytometry analysis indicated that ISL induced G2/M phase arrest. ISL enhanced the expression of LC3BⅡ protein associated with autophagy. Further, ISL inhibited migration of cancer cells. These findings suggest that ISL is a candidate agent for the treatment of endometrial cancer and ovarian cancer.

參考文獻


Aida K, Tawata M, Shindo H, Onaya T, Sasaki H, Yamaguchi T, Chin M and Mitsuhashi H. (1990) Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med. 56:254–258.
American Cancer Society, 2015
Ashkenazi A and Dixit VM. (1998) Death receptors: signaling and modulation. Science. 281:1305–1308.
Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelárová H and Meijer AJ. (1997) The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem. 243:240 – 246.
Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lannom L and Hoover RN. (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 167:1317–1325.

延伸閱讀